Cargando…
The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
BACKGROUND: The proportion of tumors of various histologies that may respond to drugs targeted to molecular alterations is unknown. NCI-MATCH, a collaboration between ECOG-ACRIN Cancer Research Group and the National Cancer Institute, was initiated to find efficacy signals by matching patients with...
Autores principales: | Flaherty, Keith T, Gray, Robert, Chen, Alice, Li, Shuli, Patton, David, Hamilton, Stanley R, Williams, Paul M, Mitchell, Edith P, Iafrate, A John, Sklar, Jeffrey, Harris, Lyndsay N, McShane, Lisa M, Rubinstein, Larry V, Sims, David J, Routbort, Mark, Coffey, Brent, Fu, Tony, Zwiebel, James A, Little, Richard F, Marinucci, Donna, Catalano, Robert, Magnan, Rick, Kibbe, Warren, Weil, Carol, Tricoli, James V, Alexander, Brian, Kumar, Shaji, Schwartz, Gary K, Meric-Bernstam, Funda, Lih, Chih-Jian, McCaskill-Stevens, Worta, Caimi, Paolo, Takebe, Naoko, Datta, Vivekananda, Arteaga, Carlos L, Abrams, Jeffrey S, Comis, Robert, O’Dwyer, Peter J, Conley, Barbara A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7566320/ https://www.ncbi.nlm.nih.gov/pubmed/31922567 http://dx.doi.org/10.1093/jnci/djz245 |
Ejemplares similares
-
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
por: Flaherty, Keith T., et al.
Publicado: (2020) -
The New NCI Precision Medicine Trials
por: Harris, Lyndsay N., et al.
Publicado: (2023) -
COVID-19, Social Justice, and Clinical Cancer Research
por: Doroshow, James H, et al.
Publicado: (2020) -
Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
por: Wisinski, Kari B., et al.
Publicado: (2023) -
Phase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
por: Clark, Amy S., et al.
Publicado: (2023)